Thymoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Thymus Cancer (53)

Thymic Carcinoma (32)

Thymus Cancer (53)

Thymic Carcinoma (32)

›

No biomarker	Thymoma	No biomarker	Thymoma	GEM-CAP Sensitive: A2 - Guideline GEM-CAP Sensitive : A2	GEM-CAP Sensitive: A2 - Guideline GEM-CAP Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	LV5FU2 Sensitive: A2 - Guideline LV5FU2 Sensitive : A2	LV5FU2 Sensitive: A2 - Guideline LV5FU2 Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	VIP Sensitive: A2 - Guideline VIP Sensitive : A2	VIP Sensitive: A2 - Guideline VIP Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	CAP Sensitive: A2 - Guideline CAP Sensitive : A2	CAP Sensitive: A2 - Guideline CAP Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	CAP + prednisone Sensitive: A2 - Guideline CAP + prednisone Sensitive : A2	CAP + prednisone Sensitive: A2 - Guideline CAP + prednisone Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	ADOC Sensitive: A2 - Guideline ADOC Sensitive : A2	ADOC Sensitive: A2 - Guideline ADOC Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	EP Sensitive: A2 - Guideline EP Sensitive : A2	EP Sensitive: A2 - Guideline EP Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	pembrolizumab Resistant: A2 - Guideline pembrolizumab Resistant : A2	pembrolizumab Resistant: A2 - Guideline pembrolizumab Resistant : A2
No biomarker	Thymoma	No biomarker	Thymoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
IGF1R expression	Thymoma	IGF1R expression	Thymoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
EIF4EBP1 expression	Thymoma	EIF4EBP1 expression	Thymoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
PD-L1 overexpression	Thymoma	PD-L1 overexpression	Thymoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4

Thymoma

Associations(21)

Associations
(21)